methyl p-isopropoxybenzyl ketone | 84023-37-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl p-isopropoxybenzyl ketone
• 英文别名: 1-(4-Isopropoxyphenyl)propan-2-one；1-(4-propan-2-yloxyphenyl)propan-2-one
• CAS: 84023-37-0
• 化学式: C₁₂H₁₆O₂
• mdl: MFCD00461574
• 分子量: 192.258
• InChiKey: HBMPUJYWIFQALP-UHFFFAOYSA-N

物化性质

• 沸点：
  110-111 °C(Press: 1 Torr)
• 密度：
  1.1377 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1R)-2-氨基-1-(3-氯苯基)乙醇 、 methyl p-isopropoxybenzyl ketone 在 sodium borohydrid 作用下， 生成 N-[2-(4-isopropoxyphenyl)-1-methylethyl]-2-hydroxy-2-(3-chlorophenyl)ethanamine
  参考文献：
  名称：

  Secondary amines

  摘要：

  该公式（II）的化合物：##STR1##或其盐；其中R.sup.1为氢或甲基，R.sup.2为氢或甲基，R.sup.3为氢，C.sub.1-12直链或支链烷基，C.sub.3-10环烷基，苯基(C.sub.1-4)-烷基或苄基，可选择地被C.sub.1-4烷基，C.sub.1-4烷氧基或卤素取代；R.sup.4为氢，卤素，羟基，C.sub.1-4烷基或C.sub.1-4烷氧基，R.sup.5为氢或氟，R.sup.6为氢或氟，R.sup.7为卤素；n为1或2，具有抗肥胖和/或抗高血糖活性。

  公开号：

  US04622342A1
• 作为产物：
  描述：

  4-异丙氧基苯甲醛 在 sodium hydroxide 、 sodium ethanolate 作用下， 以 苯 为溶剂， 反应 11.0h， 生成 methyl p-isopropoxybenzyl ketone
  参考文献：
  名称：

  Kuroyan, R. A.; Markosyan, A. I.; Engoyan, A. P., Journal of Organic Chemistry USSR (English Translation), 1983, vol. 19, p. 1709 - 1714

  摘要：

  DOI：

文献信息

• Arylethanol amine derivatives, their preparation and use in pharmaceutical compositions
  申请人：BEECHAM GROUP PLC

  公开号：EP0066351A1

  公开（公告）日：1982-12-08

  Compounds of formula (II); or a salt thereof; wherein R' is hydrogen or methyl: R2 is hydrogen or methyl; R3 is hydrogen, C1-12 C1-12 cycloalkyl, or benzyl optionally substituted with C1-6 alkyl, C1-6 alkoxy, or halogen, n is 1 or 2; and A is hydrogen, halogen, hydroxyl, C1-6 alkyl or C1-6 alkoxy; are useful in treating obesity, diabetes, or inflammation, or inhibiting platelet aggregation.

  式（II）化合物或其盐，其中 R' 是氢或甲基：R2 是氢或甲基；R3 是氢、C1-12 C1-12 环烷基或任选被 C1-6 烷基、C1-6 烷氧基或卤素取代的苄基，n 是 1 或 2；以及 A 是氢、卤素、羟基、C1-6 烷基或 C1-6 烷氧基；这些化合物可用于治疗肥胖症、糖尿病或炎症，或抑制血小板聚集。
• Secondary phenyl ethanol amines and their pharmaceutical use
  申请人：BEECHAM GROUP PLC

  公开号：EP0070134A1

  公开（公告）日：1983-01-19

  Compounds of formula (II): or salt thereof; wherein R1 is hydrogen or methyl, R2 is hydrogen or methyl, R3 is hydrogen, C1-12 straight or branched alkyl, C3-10 cycloalkyl, phenyl(C1-4)-alkyl or benzyl optionally substituted by C1-4 alkyl, C1-4 alkoxy or halogen; R4 is hydrogen, halogen, hydroxy, C1-4 alkyl or C1-4 alkoxy, R5 is hydrogen or fluorine, R6 is hydrogen or fluorine, R7 is halogen; and n is 1 or 2, have anti-obesity andior anti-hyperglycaemic activity.

  式(II)化合物 或其盐类；其中 R1 是氢或甲基 R2 是氢或甲基 R3 是氢、C1-12 直链或支链烷基、C3-10 环烷基、苯基（C1-4）-烷基或任选被 C1-4 烷基、C1-4 烷氧基或卤素取代的苄基； R4 是氢、卤素、羟基、C1-4 烷基或 C1-4 烷氧基、 R5 是氢或氟 R6 是氢或氟 R7 是卤素 n 为 1 或 2，具有抗肥胖和抗高血糖活性。
• KUROYAN, R. A.;MARKOSYAN, A. I.;ENGOYAN, A. P.;VRTANYAN, S. A., ZH. ORGAN. XIMII, 1983, 19, N 9, 1947-1953
  作者：KUROYAN, R. A.、MARKOSYAN, A. I.、ENGOYAN, A. P.、VRTANYAN, S. A.

  DOI：——

  日期：——
• NOVEL NPR-B AGONISTS
  申请人：Hellberg Mark R.

  公开号：US20110112038A1

  公开（公告）日：2011-05-12

  Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF BCR-ABL POSITIVE LYMPHOBLASTIC LEUKEMIAS
  申请人：ST. JUDE CHILDREN'S RESEARCH HOSPITAL

  公开号：US20150133462A1

  公开（公告）日：2015-05-14

  In one aspect, the invention relates to compositions comprising BCR-ABL tyrosine kinase inhibitors and artemisinin analogues, derivatives thereof, or related compounds, which are useful as in treating Philadelphia chromosome positive leukemias; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with BCR-ABL dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.